Atrium Therapeutics RNA 深 沪
已收盘 08-14 16:00:00 美东时间
12.84
+0.510
+4.14%
华盛通- 最 高12.97
- 今 开12.21
- 成交量 17.61万股
- 最 低 12.08
- 昨 收 12.33
- 总市值 2.20亿
- 52周最高 73.06
- 市盈率 静 --
- 换手率 1.03%
- 52周最低 11.13
- 委 比 9.59%
- 总股本 1710.56万
- 历史最高 73.06
- 量 比 1.73
- 振 幅 7.22%
- 历史最低 4.825
- 每 手 1
- 风险率 26.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.
08-15 01:27
财报速睇 | Atrium Therapeutics 2026财年Q2营收0.03亿美元，同比下降21.9%；归母净利润亏损0.20亿美元，同比亏损扩大56.7%
华盛资讯8月14日讯，Atrium Therapeutics公布2026财年Q2业绩，公司Q2营收0.03亿美元，同比下降21.9%，归母净利润亏损0.20亿美元，同比亏损扩大56.7%。
08-14 05:32
财报速睇 | Atrium Therapeutics 2026财年Q2营收0.03亿美元，同比下降21.9%；归母净利润亏损0.20亿美元，同比亏损扩大56.7%
华盛资讯8月14日讯，Atrium Therapeutics公布2026财年Q2业绩，公司Q2营收0.03亿美元，同比下降21.9%，归母净利润亏损0.20亿美元，同比亏损扩大56.7%。
08-14 05:22
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of $(1.21) per share from the same period last year. The company reported quarterly sales of $3.004 mil...
08-14 04:49
Atrium Therapeutics, Inc. (RNA) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Atrium Thera...
08-14 01:15
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $25.
08-06 19:12
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA)
In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rat...
07-16 17:45
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome
07-14 18:33
